CYTK Stock Overview
A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Cytokinetics, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$49.10 |
| 52 Week High | US$110.25 |
| 52 Week Low | US$30.68 |
| Beta | 0.78 |
| 11 Month Change | -4.33% |
| 3 Month Change | -13.97% |
| 1 Year Change | 53.58% |
| 33 Year Change | 25.80% |
| 5 Year Change | 407.76% |
| Change since IPO | -49.17% |
Recent News & Updates
Recent updates
Cytokinetics: On The Cusp Of Commercialization
Nov 14Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities
Aug 13Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?
Aug 11
Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes
Jul 24Cytokinetics Decides To Go It Alone
May 24Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being
May 09Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Jan 12Shareholder Returns
| CYTK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.2% | 2.5% | 2.2% |
| 1Y | 53.6% | 16.1% | 31.6% |
Return vs Industry: CYTK exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: CYTK exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| CYTK volatility | |
|---|---|
| CYTK Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CYTK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CYTK's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 423 | Robert Blum | www.cytokinetics.com |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Cytokinetics, Incorporated Fundamentals Summary
| CYTK fundamental statistics | |
|---|---|
| Market cap | US$5.79b |
| Earnings (TTM) | -US$576.40m |
| Revenue (TTM) | US$3.22m |
1,800x
P/S Ratio-10.1x
P/E RatioIs CYTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTK income statement (TTM) | |
|---|---|
| Revenue | US$3.22m |
| Cost of Revenue | US$330.76m |
| Gross Profit | -US$327.54m |
| Other Expenses | US$248.87m |
| Earnings | -US$576.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.88 |
| Gross Margin | -10,175.09% |
| Net Profit Margin | -17,906.24% |
| Debt/Equity Ratio | -5,568.4% |
How did CYTK perform over the long term?
See historical performance and comparison